Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03376789 · ClinicalTrials.gov registry record · Phase 3

Mylan Insulin Glargine Study

A Phase 3 study, sponsored by Mylan.

Completed
Registry status
Phase 3
Development phase
219
Enrollment target

NCT03376789: Completed Phase 3 study, sponsored by Mylan.

NCT03376789 is a Phase 3 study that has completed, run by Mylan. The registered enrollment target is 219 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03376789, a Phase 3 study, has completed, sponsored by Mylan.

COMPLETED
Registry status
Phase 3
Development phase
219 participants
Enrollment target

Study Summary

The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).

Primary Outcome

Change in HbA1c from baseline

Interventions

  • DRUG MYL-1501D product using manufacture process V
  • DRUG MYL-1501D product using manufacture process VI

Trial Details

FieldValue
Enrollment Target 219 participants
Start Date 2017-11-29
Est. Completion 2019-01-10
Phase Phase 3
Mylan

22 total trials

What the finished NCT03376789 record still lists

NCT03376789 is an interventional study that assigns participants to a tested intervention. The registered 219 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 2 interventions - of which MYL-1501D product using manufacture process V is the first listed.

NCT03376789 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03376789 about?

NCT03376789 is a clinical study titled "Mylan Insulin Glargine Study". The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1 diabetes mellitus (T1DM).

What is the current status of trial NCT03376789?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2017-11-29. Estimated completion is 2019-01-10.

What interventions are being tested in trial NCT03376789?

The interventions under investigation include: MYL-1501D product using manufacture process V (DRUG), MYL-1501D product using manufacture process VI (DRUG).

Who is sponsoring clinical trial NCT03376789?

This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03376789's enrollment target sits among peer trials

219 1329th of 2000 higher than 670 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05196035 · 219 participants · Phase 3

    A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

  • NCT05608434 · 219 participants · Phase 1

    Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

  • NCT05773144 · 219 participants · NA

    Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

  • NCT05907980 · 219 participants · Phase 1

    A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03376789, the US trial registry maintained by the National Library of Medicine. NCT03376789 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.